Scapa Group (SCPA)

Sector:

Industrial Chemicals

Index:

FTSE AIM 50

231.50p
   
  • Change Today:
    -1.50p
  • 52 Week High: 434.60p
  • 52 Week Low: 157.00p
  • Currency: UK Pounds
  • Shares Issued: 155.24m
  • Volume: 162,617
  • Market Cap: £359.39m
  • RiskGrade: 301
  • Beta: 0.92

Deal with Barclays    Trade now with Barclays Stockbrokers

Scapa buys Acelity's advanced wound dressings facility

By Michele Maatouk

Date: Thursday 13 Sep 2018

LONDON (ShareCast) - (Sharecast News) - AIM-listed Scapa has announced the acquisition of Acelity's advanced wound dressings manufacturing facility in Gargrave for £31m in cash.
The healthcare company has also entered into an exclusive five-year manufacturing supply agreement with Acelity for Systagenix advanced wound care products, expanding its existing partnership with the group.

Scapa said the aaddition of the well invested 335,000-square-foot Gargrave site will it as one of the leading global B2B manufacturers of advanced wound care products.

It said the acquisition "significantly" enhances its capabilities, services and footprint and adds gamma sterilisation to its capability, providing a unique value proposition and additional flexibility. In addition, it further deepens Scapa's strategic relationship with Acelity and brings to the group 22 research and developments scientists with 196 years of combined experience.

The deal will help maximise operational efficiencies for the healthcare business, Scapa said, adding that the acquired operations have existing third party contract manufacturing operations and a sterilisation business operated out of Gargrave.

Group chief executive Heejae Chae said: "The transaction marks a milestone in our healthcare journey from a material supplier to a global healthcare company. It bridges the final gaps in our value proposition in capabilities, services and footprint. The Gargrave facility will serve as our European centre of excellence with its state of the art manufacturing facility and significant innovation and development capability.

"Additionally, the transaction will further strengthen our strategic relationship with Acelity by supporting its strategy for continued growth as the leading wound care company in the world."

At 1600 BST, the shares were up 5.8% to 433.60p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Scapa Group Market Data

Currency UK Pounds
Share Price 231.50p
Change Today -1.50p
% Change -0.64 %
52 Week High 434.60p
52 Week Low 157.00p
Volume 162,617
Shares Issued 155.24m
Market Cap £359.39m
Beta 0.92
RiskGrade 301

Scapa Group Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
78.66% below the market average78.66% below the market average78.66% below the market average78.66% below the market average78.66% below the market average
14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average14.29% below the sector average
Price Trend
80.47% below the market average80.47% below the market average80.47% below the market average80.47% below the market average80.47% below the market average
42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average42.86% below the sector average
Income
79.72% below the market average79.72% below the market average79.72% below the market average79.72% below the market average79.72% below the market average
71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average71.43% below the sector average
Growth
23.64% below the market average23.64% below the market average23.64% below the market average23.64% below the market average23.64% below the market average
26.32% below the sector average26.32% below the sector average26.32% below the sector average26.32% below the sector average26.32% below the sector average

What The Brokers Say

Strong Buy 3
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 4
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Scapa Group Dividends

  Latest Previous
  Final Final
Ex-Div 25-Jul-19 19-Jul-18
Paid 23-Aug-19 17-Aug-18
Amount 2.90p 2.40p

Trades for 18-Nov-2019

Time Volume / Share Price
16:35 12,973 @ 231.50p
16:29 172 @ 231.50p
16:29 94 @ 231.50p
16:29 18 @ 231.50p
16:29 42 @ 231.50p

Scapa Group Key Personnel

CEO Heejae Chae
CFO Oskar Zahn

Top of Page